Clinical Trials Directory

Trials / Completed

CompletedNCT01069003

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
2,272 (actual)
Sponsor
Medtronic Vascular · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet therapy (DAPT) drug regimen.

Detailed description

To provide clinical information on rates of late and very late stent thrombosis after Endeavor Drug-eluting Stent (DES)placement in an all comers population with a broad range of bleeding and thrombosis risk. EDUCATE will further analyze the current practice of clinicians regarding temporary cessation of antiplatelet therapy and its association with clinical outcomes. In addition, patients included in this broad Endeavor registry will also be contributed to the DAPT native study population for analysis of 12 vs 30 months duration of dual antiplatelet therapy.

Conditions

Interventions

TypeNameDescription
DRUGPlacebo ArmPlacebo and ASA (75 mg - 325 mg)
DRUGThienopyridine TherapyPrasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
DEVICESurveillance ArmNon randomized arm to understand clinical outcomes in a commercial setting

Timeline

Start date
2010-04-01
Primary completion
2014-04-01
Completion
2014-04-01
First posted
2010-02-17
Last updated
2016-01-20
Results posted
2016-01-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01069003. Inclusion in this directory is not an endorsement.